Study of T-DXd in Chinese breast cancer patients
Treatments studied
Part of Cancer, Skin clinical trials.
This study looks at how well Trastuzumab Deruxtecan (T-DXd) works in Chinese women with breast cancer that has spread. It is for people whose cancer is either HER2-positive or HER2-low and who have already had some treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have breast cancer that has spread to other parts of the body or cannot be removed by surgery
- Your cancer is either HER2-positive or HER2-low (your doctor will confirm this)
- You have already received at least one treatment for your advanced breast cancer
- You are not pregnant or breastfeeding
- You are willing to start treatment with Trastuzumab Deruxtecan (T-DXd) or have started it within the last 14 days
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows women with advanced breast cancer (metastatic) who have hormone-receptor positive tumors and low HER2 levels, to see how well a new drug called Trastuzumab Deruxtecan works when used in routine clinical care after prior hormone therapy.
This trial tests a combination of two drugs, T-DXd (a targeted therapy) and an immunotherapy, before surgery for people with early-stage breast cancer that has low levels of HER2 and is hormone receptor positive. The goal is to see if this treatment can shrink the tumor or eliminate cancer cells before surgery.
This trial tests a targeted antibody-drug medicine (trastuzumab deruxtecan, T-DXd) in people with metastatic breast cancer that is HER2-low or HER2 IHC 0. It may help by treating tumors that haven’t previously received anti-HER2 treatment in the metastatic setting.
This trial tests how well an imaging test can predict the effectiveness of the drug T-DXd in people with HER2-positive breast cancer that has spread to the brain. It aims to see if a special scan can help guide treatment.
This study tests the safety of the drug Trastuzumab Deruxtecan (T-DXd) in Indian patients with a specific type of advanced breast cancer (called HER2-positive) that has spread and cannot be removed by surgery. It is for patients who have already received anti-HER2 treatment.
This study is testing a new drug called trastuzumab deruxtecan (also known as T-DXd) in women with advanced breast cancer that is hormone receptor positive and has a very low level of HER2 (called HER2-ultralow). The trial aims to see if this drug can help shrink or slow the growth of the cancer in this specific group of patients.
Hear when a new HER2-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.